Primary Sclerosing Cholangitis (PSC) Patient Pool Analysis Market to Reach USD 632.4 Million by 2034

Pune, India - December 2025 - The global Primary Sclerosing Cholangitis (PSC) Patient Pool Analysis Market, valued at USD 359.8 million in 2024, is projected to reach USD 632.4 million by 2034, growing at a 5.6% CAGR (2025-2034), according to Exactitude Consultancy. Increasing autoimmune disease prevalence, improved hepatology diagnostics, and strengthened epidemiological tracking are refining PSC patient identification worldwide.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71979

Market Summary
The PSC Patient Pool Analysis Market is growing steadily as medical awareness increases around this rare, progressive autoimmune liver disorder characterized by chronic inflammation and fibrosis of intrahepatic and extrahepatic bile ducts. PSC is closely associated with inflammatory bowel disease (IBD)-particularly ulcerative colitis-and presents a heightened long-term risk of cholangiocarcinoma, colorectal cancer, and liver failure.

Advancements in diagnostic modalities-including MRCP (Magnetic Resonance Cholangiopancreatography), ERCP, liver biopsy, fibroscan technologies, serologic autoimmune panels, and AI-supported imaging-are significantly improving early detection and staging accuracy. Strengthened clinical registries in North America and Europe, along with rising healthcare digitalization in Asia-Pacific, are enhancing epidemiology models and expanding the documented patient pool. The increasing use of risk stratification tools, non-invasive fibrosis assessment, and regular cancer surveillance is further contributing to improved patient monitoring.

Key Takeaways
• 2024 Market Size: USD 359.8 Million
• 2034 Forecast: USD 632.4 Million
• CAGR: 5.6% (2025-2034)
• Improved MRCP access & IBD-linked screening boosting patient identification
• PSC registries expanding real-world patient datasets
• Asia-Pacific expected to record fastest growth due to healthcare modernization

Market Drivers
• Rising global autoimmune disease prevalence
• Increased linkage between PSC and ulcerative colitis driving monitoring
• Widespread use of MRCP for non-invasive bile duct visualization
• Growth in liver fibrosis assessment and cancer surveillance programs
• Improved patient registries and real-world evidence platforms

Segmentation Snapshot
By Disease Classification
• Small-Duct PSC
• Large-Duct PSC
• Overlap Syndromes (PSC-Autoimmune Hepatitis)

By Diagnostic Approach
• MRCP (Primary Diagnostic Modality)
• ERCP
• Liver Biopsy
• Blood Biomarkers & Serology
• Fibroscan / Elastography
• AI-Enhanced Imaging

By Associated Conditions
• Ulcerative Colitis
• Crohn's Disease
• Cholangiocarcinoma
• Colorectal Cancer Risk Groups

By End User
• Hospitals
• Hepatology Centers
• Gastroenterology Clinics
• Diagnostic Laboratories
• Research & Epidemiology Institutes

By Region
• North America (Largest Registry Coverage)
• Europe
• Asia-Pacific (Fastest Growing)
• Latin America
• Middle East & Africa

Explore Full Report here: https://exactitudeconsultancy.com/reports/71979/primary-sclerosing-cholangitis-psc-patient-pool-analysis-market

Recent Developments
• Expansion of PSC patient registries improving prevalence estimates.
• Increased utilization of MRCP for early and repeated bile duct evaluation.
• AI-assisted imaging tools entering hepatology diagnostics research.
• Growing clinical trials for antifibrotic and immunomodulatory agents.

Expert Quote - Irfan Tamboli, Business Development Executive
"PSC remains one of the most challenging autoimmune liver disorders to diagnose and manage. With rising awareness, improved imaging technologies, and stronger epidemiology frameworks, healthcare systems are now documenting the PSC patient pool with greater accuracy."

Conclusion
The PSC Patient Pool Analysis Market will continue expanding through 2034 as diagnostic adoption grows, patient registries improve, and autoimmune liver disease awareness strengthens globally. Organizations focusing on hepatology diagnostics, MRCP innovation, fibrosis assessment, and long-term patient monitoring platforms will lead future advancements in PSC epidemiology.

This report is also available in the following languages : Japanese (原発性硬化性胆管炎(PSC)患者プール分析、市場), Korean (원발성 경화성 담관염(PSC) 환자 풀 분석, 시장), Chinese (原发性硬化性胆管炎 (PSC) 患者群体分析,市场), French (Analyse du marché des patients atteints de cholangite sclérosante primitive (CSP)), German (Analyse des Patientenpools bei primär sklerosierender Cholangitis (PSC), Markt), and Italian (Analisi del pool di pazienti con colangite sclerosante primitiva (PSC), mercato), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/71979

Related Reports
Primary Biliary Cholangitis Market
https://exactitudeconsultancy.com/reports/71125/primary-biliary-cholangitis-market

Spasticity Market
https://exactitudeconsultancy.com/reports/72074/spasticity-market

Walking Impairment in Multiple Sclerosis Market
https://exactitudeconsultancy.com/reports/72121/walking-impairment-in-multiple-sclerosis-market

Amyotrophic Lateral Sclerosis Clinical Market
https://exactitudeconsultancy.com/reports/73649/amyotrophic-lateral-sclerosis-clinical-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.